Altshuler Shaham
SCNI

Altshuler Shaham’s Scinai Immunotherapeutics SCNI Stock Holding History

Altshuler Shaham’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed – – 286
2018
Q2 		$0 Hold
1
– – ﹤0.01% 253
2018
Q1 		$0 Hold
1
– – ﹤0.01% 223
2017
Q4 		$0 Buy
+1
New +$6.29K ﹤0.01% 162

Other funds holding SCNI

II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $1.5B AUM 26.39% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Altshuler Shaham's SCNI Position: Q3 2018 in Review

Altshuler Shaham sold out of Scinai Immunotherapeutics (SCNI) in Q3 2018, closing a stake of 1 share.

Altshuler Shaham first reported a position in SCNI in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q2 2018. 10 funds tracked by Wall St. Rank hold SCNI as of Q3 2018.

  • Altshuler Shaham reported no remaining Scinai Immunotherapeutics position as of Q3 2018 after selling out during the quarter.
  • Altshuler Shaham sold 1 Scinai Immunotherapeutics share in Q3 2018.
  • Altshuler Shaham first reported a position in Scinai Immunotherapeutics in Q4 2017 and held it in 3 quarters.
  • Altshuler Shaham's Scinai Immunotherapeutics position peaked at $0 in Q2 2018.
  • 10 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2018.

Based on Altshuler Shaham's 13F filing for Q3 2018, filed 13 Nov 2018.